News Trump disbands business forums as CEOs quit J&J's CEO Gorsky also quit before Trump axed councils
News Janssen/AbbVie drug approved in graft-versus-host disease First use for Imbruvica outside blood cancer.
News FDA advisers reject J&J rheumatoid arthritis drug Expert panel concerned about safety of sirukumab.
Views & Analysis A radical re-thinking of healthcare – J&J’s push for ‘immorb... J&J: don’t just treat disease, prevent it and intercept it.
News J&J's psoriasis drug faces crowded market after US approval J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
News Novartis' psoriasis drug gets label boost New label shows Cosentyx is superior to J&J's rival in long-term.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
